

Benedikte Hasselbalch, MD

Department of Radiation Biology,

The Finsencenter, Section 6321
Copenhagen University Hospital,
Blegdamsvej 9
DK - 2100 Copenhagen
Email: benedikte.hasselbalch@rh.regionh.dk
Phone: (+45) 35 45 63 31 Fax: (+45) 35 45 63 01

Born: September 27th, 1974

Current Position: Ph.d student

Education: Medical Doctor, 2002

Research and Professional Experiences:

1990 – 1993 High school, Hjoerring Gymnasium
1995 – 2002 Medical student, University of Odense, Denmark
2002 – 2004 Residency in Fyens county, Denmark
2004 – 2004 M.D., Faaborg Hospital
2004 – 2006 M.D., Department of Oncology, The Finsencenter, Copenhagen University Hospital
2005 – 2005 Research assistant, Department of Radiation Biology, The Finsencenter, Copenhagen University Hospital
2006 – 2009 Ph.D student at Department of Radiation Biology, The Finsencenter, Copenhagen University Hospital. PhD thesis submitted December 2009
2010 Research assistant at Department of Radiation Biology, The Finsencenter, Copenhagen University Hospital
2010 M.D., Roskilde Sygehus

Grants and Scholarships:

2005 Awarded a travel grant from the Danish Cancer Society
2005 Awarded a scholarship from American Association for Cancer Research, attending a workshop in cancer research
2007 Awarded a travel grant from the Danish Cancer Society
2008 Awarded a travel grant from the Danish Cancer Society
2009 Awarded a research grant from Læge Agnete Løvgreens legat
2009 The Young Investigator Award, at the Scandinavian Neuro-Oncology Society Meeting, Helsingfors, Finland

Conferences and Meetings:

2005 Oral presentation at SKA, post-ASCO meeting, Copenhagen

2007 **B. Hasselbalch**, M.T. Stockhausen, U. Lassen, H.S. Poulsen. *"In Vitro Effects of cetuximab on EGFR and Down Stream Mediators, with a focus on gliomas"*. Poster presentation at the 20th Annual Meeting of the Danish Association for Cancer Research, Charlottenlund, Denmark

2007 **B. Hasselbalch**. *"Bevacizumab, a monoclonal antibody to the Vascular Endothelial Growth Factor (VEGF) and Irinotecan for treatment of recurrent primary malignant brain tumors in adults"* and **B. Hasselbalch**. *"In Vitro Effects of cetuximab on EGFR & Downstream mediators"*. Oral presentations at the Scandinavian Neuro-Oncology Society Meeting, Copenhagen, Denmark

- 2007 **B. Hasselbalch**, U. Lassen, K. Grunnet, M. Kostaljanetz, H Laursen, H.S Poulsen. "Bevacizumab, a monoclonal antibody to the Vascular Endothelial Growth Factor (VEGF), and Irinotecan for treatment of recurrent primary malignant brain tumors in adults" and **B. Hasselbalch**, M.T. Stockhausen, U. Lassen. H.S. Poulsen. "*In Vitro Effects of cetuximab on EGFR and Down Stream Mediators, with a focus on gliomas*". Poster presentation at Society for Neuro-Oncology's 12th Annual Scientific Meeting, Dallas, TX, USA:
- 2008 **B. Hasselbalch**. "*In Vitro Effects of cetuximab on EGFR & Downstream mediators with a focus on gliomas*". Oral presentation at Dansk Selskab for Klinisk Onkologi (DSKO) Annual Meeting, Vejle, Denmark
- 2008 **B. Hasselbalch**, U. Lassen, M. Sørensen, S. Hansen, M. Holmberg, M. Kosteljanetz, H. Broholm, HS. Poulsen "A phase II trial with cetuximab, bevacizumab and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolomide". Poster presentation at the 21th Annual Meeting of the Danish Association for Cancer Research, Charlottenlund
- 2008 **B. Hasselbalch**, U. Lassen, M. Sørensen, S. Hansen, M. Holmberg, M. Kosteljanetz, H. Broholm, HS. Poulsen "A phase II trial with cetuximab, bevacizumab and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolomide". Poster presentation at the Society for Neuro-Oncology's 13th Annual Scientific Meeting, Las Vegas, NV, USA
- 2009 **B. Hasselbalch**, U. Lassen, M.T. Stockhausen, I.J. Christensen, J.G. Eriksen, H. Broholm, M. Holmberg, S. Hansen, M. Sørensen, K. Grunnet, H. S. Poulsen. "*Immunohistochemical evaluation of high-grade glioma patients treated with bevacizumab and irinotecan, with or without cetuximab*". Poster presentation at the Scandinavian Neuro-Oncology Society Meeting, Helsingfors, Finland
- 2009 **B. Hasselbalch**, U. Lassen, M.T. Stockhausen, I.J. Christensen, J.G. Eriksen, H. Broholm, M. Holmberg, S. Hansen, M. Sørensen, K. Grunnet, H. S. Poulsen. "*Immunohistochemical evaluation of high-grade glioma patients treated with bevacizumab and irinotecan, with or without cetuximab*". Poster presentation at Society for Neuro-Oncology's 14th Annual Scientific Meeting, New Orleans, LA, USA

Publications with peer-review:

Poulsen HS, Grunnet K, Sorensen M, Olsen P, **Hasselbalch B**, Nelausen K, Kosteljanetz M, Lassen U. *Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours*. Acta Oncol. Oct 2009; 48: 52-58

Hasselbalch B., Lassen, U. Poulsen, HS Poulsen and Stockhausen MT. *Cetuximab is insufficient in inhibiting glioma cell growth due to persistent EGFR downstream signalling*. In press Cancer Investigation 2009.

Sørensen M, Gaziel TB, **Hasselbalch B**, Poulsen HS, Lassen U. *Severe Skin Lesions in Patients with Glioblastoma Multiforme Treated with a Combination of Cetuximab, Bevacizumab, and Irinotecan*. European Journal of Clinical and Medical Oncology 2009

Hasselbalch B., Lassen U., Hansen S., Holmberg M., Sørensen M., Kosteljanetz, M., Broholm H., Stockhausen MT., Poulsen HS. *Cetuximab, Bevacizumab and Irinotecan for Patients With Primary Glioblastoma and Progression After Radiation Therapy and Temozolomide: A Phase II Trial*. Journal of Neuro-Oncology, 2010;12(5):508-516

Hasselbalch B., Eriksen JG., Broholm H., Christensen IJ., Grunnet K., Horsman MR., Poulsen HS., Stockhausen MT., Lassen U. *Prospective evaluation of angiogenic, hypoxic and EGFR related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan*. In press APMIS 2010.

Publications without peer-review:

Hasselbalch B, Lassen U, Poulsen HS. *Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan*. Book chapter in "TUMORS OF THE CENTRAL NERVOUS SYSTEM" edited by M.A. Hayat. In press
